AFLAC INC Annual Report, Year Ended Dec 31, 2018

Aflac Incorporated's 2018 10-K filing reveals a company largely driven by its Japanese operations, which accounted for approximately 70% of total revenues and 84% of total assets. The company's core business remains voluntary supplemental health and life insurance in both the U.S. and Japan. Key financial highlights show total revenues of $21.8 billion, a slight increase from the prior year, while net earnings saw a significant decrease to $2.9 billion from $4.6 billion in 2017. This decline is largely attributable to the absence of the substantial tax benefit recorded in 2017 due to the U.S. Tax Act. The company also experienced net realized investment losses of $430 million in 2018, primarily driven by equity security performance and derivative activities. Aflac continues to focus on product innovation, especially in Japan with new cancer and medical insurance offerings, and on expanding its distribution channels in the U.S. through group products and broker relationships. The company repurchased approximately $1.3 billion of its common stock in 2018. A significant strategic development mentioned is Japan Post Holdings' plan to purchase approximately 7% of Aflac's outstanding common shares, subject to regulatory approvals. The company's financial condition is noted as strong, with robust capital and liquidity levels, although it faces ongoing risks related to global capital markets, interest rate fluctuations, foreign currency exchange rates, and intense competition.